Clinical trial
Assessment of Trough Levels and Efficacy of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
NCT05291039 is registered in ClinicalTrials.gov with Rehab Werida as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Trough Levels and Efficacy of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
- Lead sponsor
- Rehab Werida
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- January 1, 2022
- Completion date
- April 1, 2023
- Enrollment
- 56 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.